Publication
Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab
| dc.contributor.author | Franqueira, N | |
| dc.contributor.author | Cachulo, ML | |
| dc.contributor.author | Pires, I | |
| dc.contributor.author | Fonseca, P | |
| dc.contributor.author | Marques, I | |
| dc.contributor.author | Figueira, J | |
| dc.contributor.author | Silva, R | |
| dc.date.accessioned | 2017-08-23T11:17:56Z | |
| dc.date.available | 2017-08-23T11:17:56Z | |
| dc.date.issued | 2012 | |
| dc.description.abstract | PURPOSE: To evaluate the long-term safety and efficacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (CNV). METHODS: Three-year retrospective, nonrandomized, interventional case series. Forty eyes of 39 patients with myopic CNV were included; 15 with previous photodynamic therapy, and 25 naïve eyes. Best-corrected visual acuity (BCVA) changes, central foveal thickness (CFT), and number of treatments were assessed, from baseline to month 36. RESULTS: Mean visual acuity improved from 55.4 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 59.7 letters at 12 months (p = 0.07), 61.8 letters at 24 months (p = 0.008) and 63.4 letters at 36 months (p = 0.039). Twenty-five percent of the patients gained ≥15 letters (3 lines) at 12 months, 30% at 24 months and 35% at 36 months. There was a mean reduction of 80 μm in CFT (p < 0.001). A mean of 4.1 injections were performed in the first year, 2.4 in the second year and 1.1 in the third year. Fifty-three percent of the eyes had no need for treatment during the third year of follow-up. CONCLUSIONS: Intravitreal ranibizumab seems to be an effective and safe therapeutic procedure to treat CNV in highly myopic eyes, with a high proportion of patients gaining or stabilizing BCVA at a 3-year follow-up. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Ophthalmologica. 2012;227(1):39-44. | pt_PT |
| dc.identifier.doi | 10.1159/000333213 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.4/2057 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.subject | Anticorpos Monoclonais | pt_PT |
| dc.subject | Neovascularização da Coróide | pt_PT |
| dc.subject | Miopia Degenerativa | pt_PT |
| dc.subject | Ranibizumab | pt_PT |
| dc.title | Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 44 | pt_PT |
| oaire.citation.issue | 1 | pt_PT |
| oaire.citation.startPage | 39-44 | pt_PT |
| oaire.citation.volume | 227 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |